Loading…
Maze Therapeutics, Inc. is projected to rise to $35.80 by 2027, a +17% move from its current price of $30.57. MAZE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $29.83 | $30.57 | $31.34 | +0.01% |
| Jul 14 | $29.53 | $30.58 | $31.67 | +0.03% |
| Jul 15 | $29.30 | $30.58 | $31.92 | +0.04% |
| Jul 16 | $29.11 | $30.59 | $32.14 | +0.06% |
| Jul 17 | $28.95 | $30.59 | $32.33 | +0.07% |
| Jul 18 | $28.80 | $30.60 | $32.51 | +0.09% |
| Jul 19 | $28.66 | $30.60 | $32.67 | +0.10% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $28.66 | $30.60 | $32.67 | +0.10% |
| Week 2 | $27.92 | $30.63 | $33.60 | +0.20% |
| Week 3 | $27.38 | $30.66 | $34.34 | +0.31% |
| Week 4 | $26.93 | $30.70 | $34.99 | +0.41% |
| Week 5 | $26.54 | $30.73 | $35.57 | +0.51% |
| Week 6 | $26.20 | $30.76 | $36.11 | +0.61% |
| Week 7 | $25.89 | $30.79 | $36.61 | +0.72% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Maze Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing small molecule precision medicines for kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, in phase II for APOL1 kidney disease; MZE782, an oral small molecule inhibitor in phase II ready clinical trial for phenylketonuria and chronic kidney disease; and MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase for Pompe disease.
The company has license agreements with Trace Neuroscience, Inc. to discovery research targeting UNC13A; Shionogi & Co., Ltd. to research and commercialize MZE001; and Neurocrine Biosciences, Inc.
to discover a program targeting ATXN2. Formerly Modulus Therapeutics, Inc., the firm changed its name to Maze Therapeutics, Inc. in September 2018. It was incorporated in 2017 and is based in South San Francisco, California.
Maze Therapeutics trades under the MAZE symbol and is in the Healthcare/biopharmaceutical space. The current price is $31.26, and the company carries a market capitalization of $1.73B. Its market rank is 2097. These figures frame Maze as a development-stage entity with a focused portfolio and a defined U.S. operating base.
Looking ahead, the forecast presents a path of rising average prices through 2030 and beyond, with several years showing bullish or neutral sentiment and notable upside potential. The data provide a structured view of expected price levels and potential returns across multiple years, including long-run upside illustrated by the later years.
A major floor 35.4% below — a decisive break under it would weaken the trend.
The nearest floor, 22.9% below — buyers have tended to step in here.
The nearest ceiling, 7.4% above — a clean break opens room to run.
A major ceiling 69.6% above — clearing it would confirm fresh momentum.
Key MAZE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MAZE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $32.03 | Sell | $31.41 | Sell |
| MA 10 | $30.85 | Sell | $30.58 | Sell |
| MA 20 | $28.05 | Buy | $29.04 | Buy |
| MA 50 | $26.57 | Buy | $28.45 | Buy |
| MA 100 | $32.30 | Sell | $30.31 | Buy |
| MA 200 | $34.47 | Sell | $30.20 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.02 | Neutral |
| Stoch RSI (14) | 32.32 | Neutral |
| CCI (20) | 59.98 | Neutral |
| Williams %R (14) | -31.22 | Info |
| MACD (12,26,9) | 0.45 | Buy |
| ROC (12) | 15.75 | Buy |
| Bollinger %B (20,2) | 0.70 | Neutral |
| Stochastic %K (14) | 68.78 | Neutral |
| TRIX (15) | 0.70 | Buy |
| Awesome (5,34) | 5.17 | Buy |
| Ultimate (7,14,28) | 61.51 | Neutral |
| Momentum (10) | 3.55 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 32.44 | Sell |
| ADX (14) | 32.23 | Buy |
| ATR (14) | 0.74 | Info |
The 30-day technical picture is bullish, with RSI(14) at 80 indicating strong momentum. The stock trades between a 30-day range low of $26.88 and high of $36.36, suggesting liquidity within a defined band.
Key moving averages are $25.98 for SMA50 and $34.25 for SMA200, with the short-term price facing resistance at $31.26 and support at $23.58. The combination of a bullish sentiment and the tight 30-day range points to upside potential, barring new catalysts or shifts in market momentum.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $23.58 | $30.57 | $40.12 | 0% | Neutral | |
| $28.72 | $35.80 | $47.08 | +17% | Neutral | |
| $30.46 | $38.95 | $53.01 | +27% | Bullish | |
| $37.66 | $49.18 | $68.76 | +61% | Bullish | |
| $43.61 | $58.01 | $82.98 | +90% | Bullish | |
| $47.79 | $64.65 | $94.32 | +111% | Bullish | |
| $51.99 | $71.45 | $106.11 | +134% | Bullish | |
| $50.53 | $70.46 | $106.35 | +130% | Bullish | |
| $55.15 | $77.98 | $119.47 | +155% | Bullish | |
| $62.14 | $89.04 | $138.31 | +191% | Bullish | |
| $90.90 | $138.30 | $227.67 | +352% | Bullish | |
| $166.91 | $281.29 | $504.14 | +820% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $23.58 | $30.57 | $36.73 | +0.00% |
| August 2026 | $26.73 | $31.48 | $38.01 | +2.96% |
| September 2026 | $26.14 | $30.98 | $37.80 | -1.58% |
| October 2026 | $25.69 | $30.62 | $37.69 | -1.15% |
| November 2026 | $26.36 | $31.56 | $39.12 | +3.07% |
| December 2026 | $26.74 | $32.15 | $40.12 | +1.87% |
Click any year to see its month-by-month MAZE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Maze Therapeutics, Inc.'s 2026 outlook centres on $30.57, within a $23.58 to $40.12 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, MAZE could reach as high as $47.08, with a base case around $35.80 and support toward $28.72 — roughly +17% from $30.57. A consolidation phase looks the most probable path here.
Expect MAZE to range from $30.46 to $53.01 through 2028. The $38.95 average target implies a +27% move from current prices. That is up +9% on the projected 2027 average. Momentum favours further upside here.
The MAZE price prediction for 2029 points to an average of $49.18 (low $37.66, high $68.76) — a potential gain of +61% on today's $30.57. Buyers look set to stay in control over this stretch.
In 2030, MAZE is projected to trade between $43.61 and $82.98, averaging $58.01 — a potential gain of +90% from today's $30.57. That is up +18% on the projected 2029 average. Momentum favours further upside here.
Maze Therapeutics, Inc.'s 2031 outlook centres on $64.65, within a $47.79 to $94.32 range. That is up +11% on the projected 2030 average. That marks a +111% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, MAZE could reach as high as $106.11, with a base case around $71.45 and support toward $51.99 — roughly +134% from $30.57. Momentum favours further upside here.
Expect MAZE to range from $50.53 to $106.35 through 2033. The $70.46 average target implies a +130% move from current prices. That is -1% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
The MAZE price prediction for 2034 points to an average of $77.98 (low $55.15, high $119.47) — a potential gain of +155% on today's $30.57. Momentum favours further upside here.
In 2035, MAZE is projected to trade between $62.14 and $138.31, averaging $89.04 — a potential gain of +191% from today's $30.57. That is up +14% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Maze Therapeutics, Inc.'s 2040 outlook centres on $138.30, within a $90.90 to $227.67 range. That is up +55% on the projected 2035 average. That marks a +352% change versus current levels. Momentum favours further upside here.
By 2050, MAZE could reach as high as $504.14, with a base case around $281.29 and support toward $166.91 — roughly +820% from $30.57. Buyers look set to stay in control over this stretch.
Investing $1,000 in MAZE today (≈ 32.711809 MAZE) could be worth
$9,201.36
+$8,201.36 (+820%) by 2050 · US Dollar
Based on the average projected MAZE price of $281.29 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MAZEwould be worth at today's price.
$1,000 invested in MAZE on Jul 10, 2025 (≈ 63.938618 MAZE) would be worth
$1,954.6
+$954.6 (+95.5%) today · 1.95× · US Dollar
Based on a MAZE entry price of $15.64 vs. today's $30.57.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $31.26 | $977.93 | -2.2% |
| 1 month ago | $23.66 | $1,292.05 | +29.2% |
| 3 months ago | $26.69 | $1,145.37 | +14.5% |
| 6 months ago | $40.19 | $760.64 | -23.9% |
| 1 year ago | $15.64 | $1,954.6 | +95.5% |
| All time (1.4y) ago | $15.95 | $1,916.61 | +91.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MAZE forecast.
Our base-case forecast reaches $61.00 around 2031.
Implied market cap at $61.00: $3.38B
The multi-year forecast shows sustained upside, with the 2030 average price of $60.99 and an absolute range up to $86.27, corresponding to a 95.1 ROI metric in the forecast. After 2030, the path remains bullish, continuing through the 2040 and 2050 horizons with higher average prices and elevated ROI figures (2040 average $149.31 with a 377.6 ROI, 2050 average $304.91 with an 875.4 ROI).
Beyond 2030, the yearly outlook remains bullish, with 2031 average $68.21, 2032 $74.61, 2033 $75.24, 2034 $84.02, and 2035 $94.82. The longer-dated forecasts continue to project substantial upside, culminating in 2050’s average of $304.91 and a very large ROI. These are estimates, not guarantees, and depend on market conditions and company progress.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $60.99 with a range from $46.27 to $86.27 and a ROI of 95.1.
Forecasts indicate bullish sentiment from 2028 onward, with rising averages and ROI reaching 95.1 by 2030, 377.6 by 2040, and 875.4 by 2050, though these are estimates and not guarantees.
Yes. The forecast shows a max of $111.99 in 2033 and a max of $126.85 in 2034, with a further max of $145.05 in 2035, indicating it can exceed $100 in those years.
Current price is $31.26 and market cap is $1.73B.
RSI(14) is 80 and sentiment is BULLISH. SMA50 is $25.98, SMA200 is $34.25, with a support at $23.58 and resistance at $31.26; the 30-day range is $26.88 to $36.36, indicating a bullish short-term stance.
Maze Therapeutics, Inc. Community Discussion
0Share your Maze Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.